Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 8:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 7,251 matching trials from the live ClinicalTrials.gov search.
Conditions
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
Interventions
Telemedicine, Genetic Testing, Internet-Based Intervention, Educational Intervention, Patient Navigation, Interview, Survey Administration
Other · Behavioral
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
327
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 238 more
Conditions
Neoplasms, Triple Negative Breast Cancer, Ovarian Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
niraparib, pembrolizumab
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Conditions
Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
Interventions
Atezolizumab, Biopsy, Bone Scan, Computed Tomography, Docetaxel, Magnetic Resonance Imaging, Paclitaxel, Pertuzumab, Placebo Administration, Quality-of-Life Assessment, Trastuzumab
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
662
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more
Conditions
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
Interventions
Navtemadlin, Navtemadlin placebo, Ruxolitinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
58
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 52 more
Completed No phase listed Observational Accepts healthy volunteers

Safety and Efficacy of Chronic Hypnotic Use

NCT01006525
Conditions
Primary Insomnia
Interventions
zolpidem
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
21 Years to 70 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Chronic Graft-versus-host-disease
Interventions
axatilimab
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Miami, Florida + 8 more
Completed Not applicable Interventional Results available

Preemptive Resuscitation for Eradication of Septic Shock

NCT01449721
Conditions
Sepsis, Severe Sepsis
Interventions
Intravenous fluid
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Newark, Delaware • Boston, Massachusetts • Detroit, Michigan + 2 more
Conditions
Lymphoma, Non-Hodgkin
Interventions
TAK-659, Bendamustine, Rituximab, Gemcitabine, Lenalidomide, Ibrutinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Tucson, Arizona • La Jolla, California • West Hollywood, California + 8 more
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Conditions
Advanced Solid Malignant Tumors, Advanced Ovarian Cancer
Interventions
U3-1565
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Detroit, Michigan • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 1 more
Conditions
Multiple Sclerosis
Interventions
fampridine, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Cullman, Alabama • Phoenix, Arizona • San Diego, California + 12 more
Conditions
Hodgkin Lymphoma
Interventions
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
Conditions
Influenza
Interventions
fluID Rapid Influenza Test
Device
Lead sponsor
Nanogen, Inc.
Industry
Eligibility
Not listed
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
12
States / cities
San Diego, California • DeLand, Florida • Shreveport, Louisiana + 8 more
Conditions
Colorectal Cancer
Interventions
capecitabine, celecoxib, irinotecan hydrochloride
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Columbus, Ohio
Conditions
Optic Nerve Diseases
Interventions
Zyvox - linezolid, Matched control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
7
States / cities
Jonesboro, Arkansas • West Palm Beach, Florida • New Orleans, Louisiana + 4 more
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
33
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 23 more
Conditions
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Interventions
Ticagrelor Dose 1a + Dose 2a, Ticagrelor Dose 1b + Dose 2b
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Orange, California • Chicago, Illinois • Detroit, Michigan + 3 more
Completed Phase 2 Interventional Results available

Rapid Administration of Carnitine in sEpsis

NCT01665092
Conditions
Septic Shock
Interventions
Levo-Carnitine, placebo
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
14
States / cities
Birmingham, Alabama • Sacramento, California • Wilmington, Delaware + 9 more
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Bupropion Hydrochloride Controlled-release, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
542
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 335 more
Conditions
Adult Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, Tivantinib, Topotecan Hydrochloride
Other · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 4 more
Conditions
Kidney Diseases, Coronary Artery Disease
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
41
States / cities
Anniston, Alabama • Little Rock, Arkansas • Bell Gardens, California + 36 more
Conditions
Breast Neoplasms
Interventions
SU011248, Chemotherapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
77
States / cities
Corona, California • Fullerton, California • Glendora, California + 59 more
Recruiting Not applicable Interventional

ELEVATE High-Risk PCI Pivotal Study

NCT07001332
Conditions
High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Interventions
Elevate, Impella
Device
Lead sponsor
Magenta Medical Ltd.
Industry
Eligibility
18 Years to 88 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 23 more
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
397
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more